HU 010

Drug Profile

HU 010

Alternative Names: HU010

Latest Information Update: 17 Dec 2015

Price : $50

At a glance

  • Originator Huons
  • Developer Chungnam National University; College of Medicine Korea University; Dongguk University; Huons
  • Class
  • Mechanism of Action Adenosine A3 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Stroke

Most Recent Events

  • 17 Dec 2015 No development reported - Phase-II for Stroke in South Korea (unspecified route)
  • 31 Dec 2011 Phase-II clinical trials in Stroke in South Korea (unspecified route) (Huons pipeline, December 2015)
  • 31 Dec 2008 Preclinical trials in Stroke in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top